Making a difference with your help.
Protocol Name: SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS Protocol #: TVTX-RE021-426 Indication: Cardiovascular Event Risk Reduction GFR: ≥25 Principal Investigator: Bernard Fischbach, MD, CCRP Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: AZURE: Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event Protocol #: D7960C00015 Indication: Cardiovascular Event Risk Reduction GFR: ≥15 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,
Protocol Name: ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD Protocol #: ALN-AGT01-008 Indication: HTN (Uncontrolled) GFR: <60 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: A study to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients with primary FSGS or minimal change disease Protocol #: ACT18064 Indication: Fabry Disease GFR: ≥ 45 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients Protocol #: CLI-06657AA1-10 (MODERN) Indication: Fabry Disease GFR: n/a Principal Investigator: Ankit N. Mehta, MD, FASN Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients Read More »
Protocol Name: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Protocol #: M25-147 ANCHOR Indication: Autosomal Dominant Polycystic Kidney Disease GFR: ≥30 Principal Investigator: Michael R. Wiederkehr, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000,
Protocol Name: Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype Protocol #: MZE829-201 Indication:APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 Principal Investigator: Tapan J. Patel, MD, FACP, FASN, FNKF Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,
Protocol Name: ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome Protocol #: 22419 Indication: Alport Syndrome GFR: ≥45 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS
Protocol Name: Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis Protocol #: 20220159 Indication: ANCA associated Vasculitis GFR: ≥15 Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure Protocol #: D6972C00002 Indication: CKD & HTN GFR: 30-75 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,